Cegedim SA (LON:0DYQ)
London
· Delayed Price · Currency is GBP · Price in EUR 11.25
-0.20 (-1.75%)
Apr 22, 2025, 8:11 AM BST
Cegedim Revenue
In the year 2024, Cegedim had annual revenue of 654.50M EUR with 6.25% growth. Cegedim had revenue of 335.50M in the half year ending December 31, 2024, with 16.64% growth.
Revenue
654.50M EUR
Revenue Growth
+6.25%
P/S Ratio
0.25
Revenue / Employee
97.69K EUR
Employees
6,700
Market Cap
136.36M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 654.50M | 38.50M | 6.25% |
| Dec 31, 2023 | 616.00M | 60.79M | 10.95% |
| Dec 31, 2022 | 555.21M | 30.50M | 5.81% |
| Dec 31, 2021 | 524.71M | 27.77M | 5.59% |
| Dec 31, 2020 | 496.94M | -6.81M | -1.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |